hVIVO plc hVIVO and Imutex to present at IVW 2019
29 March 2019 - 6:02PM
RNS Non-Regulatory
TIDMHVO
hVIVO plc
29 March 2019
hVIVO plc
("hVIVO" or the "Company")
hVIVO and Imutex Limited to present at the Influenza Vaccines
for the World (IVW 2019) conference at the Royal College of
Physicians of Edinburgh, Scotland
London, UK 29 March 2019: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral and allergen challenge, confirms
that the Company and its joint venture, Imutex Limited, will
present at the Influenza Vaccines for the World (IVW 2019)
conference on 2-4 April 2019 at the Royal College of Physicians of
Edinburgh, Edinburgh, Scotland, UK.
IVW 2019 is an international conference and exhibition in an
important series of influenza vaccine meetings focused on
'Influenza Vaccination Issues'. The IVW series is an international
forum for world renowned experts in the field of influenza vaccines
and related issues (adjuvants / delivery / vaccination strategies)
to report on the latest data and trends associated with current and
new influenza vaccines / technologies and their availability /
delivery / implementation worldwide.
Presentation details are as follows:
Title: FLU-v, a broad spectrum influenza vaccine:
cross-reactivity and field results
Presenter: Dr Olga Pleguezuelos, Imutex (SEEK)
Date and time: Tuesday, 2 April 2019, Session 3,12.10-12.40
Location: Royal College of Physicians of Edinburgh, Scotland, UK
Title: The future for FLU-v: Efficacy results from an H1N1 challenge study
Presenter: Dr Emma James, Imutex (SEEK)
Date and time: Tuesday, 2 April 2019, Session 4, 14.30-15.00
Location: Royal College of Physicians of Edinburgh, Scotland, UK
Title: The human viral challenge and the evaluation of novel/universal vaccines
Presenter: Dr Rob Lambkin-Williams, hVIVO
Date and time: Wednesday, 3 April 2019, Session 6, 09.30-09:50
Location: Royal College of Physicians of Edinburgh, Scotland, UK
For further information please contact:
hVIVO plc
Trevor Phillips (Executive Chairman) +44 207 756 1300
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
About FLU-v - a Phase III enabled, broad spectrum stand-alone,
universal influenza vaccine candidate:
FLU-v is a novel first-in-class, broad spectrum, true
stand-alone, influenza vaccine candidate. FLU-v is designed to
provide broad spectrum cover against multiple influenza strains and
does not require annual immunisation alongside an annual influenza
vaccine to confer immunity. It is also designed to minimise the
impact of the influenza virus by reducing symptoms, potentially
relegating influenza to a much milder disease by stimulating an
immune response mediated through T-cells and B-cells to the
internal proteins, in contrast to seasonal influenza vaccines that
prevent infection through antibody protection against external
proteins. In 2017, there were two FLU-v Phase IIb studies
conducted- 003 (field study) and 004 (human viral challenge
study).
FLU-v is a synthetic polypeptide vaccine which means that it is
not reliant on traditional manufacturing techniques with inherent
risks, in particular the potential of a mismatch of virus
particularly relevant for a pandemic strain. FLU-v is designed to
protect against a broad range of influenza viral strains and this
includes unexpected seasonal strains or a potentially devastating
pandemic strain.
FLU-v is being developed by Imutex Limited, hVIVO's 49% joint
venture with PepTcell Limited, trading as the SEEK Group
("SEEK").
About hVIVO:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial
platform to accelerate drug and vaccine development in respiratory
and infectious diseases. Leveraging human disease models in flu,
RSV, HRV and respiratory indications, the hVIVO platform captures
disease in motion, illuminating the entire disease life cycle from
healthy to sick and back to health. Based in the UK, market leader
hVIVO has conducted more than 50 clinical studies and inoculated
over 2500 volunteers.
About SEEK Group (PepTCell Limited, trading as SEEK Group):
SEEK's strategy is to bring safe, effective and low-cost
medicines to patients as quickly as possible, to radically improve
human health in major disease areas.
We do this by:
-- Modifying existing medicines to improve their efficacy
-- Using existing medicines in new indications
-- Creating new chemical entities
Working in these different ways allows us to optimise the
regulatory approval pathway to ensure that we bring safe and
effective products to patients in the shortest possible time.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGUBGWUPBGAR
(END) Dow Jones Newswires
March 29, 2019 03:02 ET (07:02 GMT)
Retroscreen (LSE:RVG)
Historical Stock Chart
From May 2024 to Jun 2024
Retroscreen (LSE:RVG)
Historical Stock Chart
From Jun 2023 to Jun 2024